<!doctype html>
<html lang="en">
<meta charset="utf-8">
<meta name="viewport" content="width=device-width, initial-scale=1">
<title>Is Vertex Pharmaceuticals Stock Underperforming the S&amp;P 500? · Newsletter</title>
<style>
:root{--bg:#0f1221;--fg:#e8ecf3;--muted:#98a2b3;--link:#74b7ff;--card:#171b2f;--btn:#2563eb;--btnText:#fff;}
*{box-sizing:border-box} body{margin:0;font-family:ui-sans-serif,system-ui,-apple-system,Segoe UI,Roboto,Inter,Arial;background:var(--bg);color:var(--fg)}
.container{max-width:920px;margin:40px auto;padding:0 16px}
.header{display:flex;justify-content:space-between;align-items:center;gap:16px}
.brand{font-size:.95rem;font-weight:700;color:#8fb5ff}
.kicker{font-size:.85rem;color:var(--muted)}
.card{background:var(--card);border-radius:14px;padding:26px;margin-top:18px;box-shadow:0 6px 24px rgba(0,0,0,.35)}
h1{font-size:2rem;margin:.2rem 0 0}
.meta{font-size:.9rem;color:var(--muted);margin:.6rem 0 1rem}
ul{margin:12px 0 18px 22px;padding:0}
li{margin:.35rem 0;line-height:1.5}
a{color:var(--link);text-decoration:none}
a:hover{text-decoration:underline}
.btns{display:flex;gap:10px;margin-top:10px}
.btn{display:inline-block;background:transparent;border:1px solid #6b7280;color:#e5e7eb;padding:8px 12px;border-radius:8px;font-size:.9rem}
.btn.primary{background:var(--btn);border-color:var(--btn);color:var(--btnText)}
.footer{margin-top:26px;font-size:.8rem;color:var(--muted);text-align:center}
hr{border:0;border-top:1px solid #2a2f48;margin:18px 0}
</style>
<body>
  <div class="container">
    <div class="header">
      <div class="brand">Daily Finance Newsletter</div>
      <div class="kicker">5–7 key bullets per story</div>
    </div>

    <div class="card">
      <h1>Is Vertex Pharmaceuticals Stock Underperforming the S&amp;P 500?</h1>
      <div class="meta">2025-09-08 12:35:30+00:00 UTC</div>
      <ul>
        <li>Moreover, its adjusted EPS of $4.52 surpassed the Street’s estimates by 6.6%.</li>
        <li>4, Vertex Pharmaceuticals released its Q2 results, and its shares plummeted 20.6%.</li>
        <li>Longer term, VRTX has plunged 1.6% on a YTD basis, lagging behind $SPX’s 10.2% rise.</li>
        <li>Shares of REGN have declined 50.2% in the last 52 weeks and 19.5% on a YTD basis.</li>
        <li>Driven by continued momentum, the company’s topline for the quarter surged 12.1% year-over-year to $2.96 billion, exceeding the consensus estimates by 2.6%.</li>
        <li>More News from Barchart - CPI, S&amp;P 500 Additions and Other Key Things to Watch this Week - Analysts Keep Raising Shopify&#x27;s Targets - Make a 3.0% Yield in One-Month SHOP OTM Puts However, the biopharmaceutical titan has f</li>
        <li>8, 2024.</li>
      </ul>
      <div class="btns">
        <a class="btn" href="https://finance.yahoo.com/m/59379879-7a6a-342d-9125-5ff3f88c0168/is-vertex-pharmaceuticals.html" target="_blank" rel="noopener nofollow">Original</a>
        <a class="btn primary" href="https://twitter.com/intent/tweet?text=Is+Vertex+Pharmaceuticals+Stock+Underperforming+the+S%26P+500%3F%0A%E2%80%A2+Moreover%2C+its+adjusted+EPS+of+%244.52+surpassed+the+Street%E2%80%99s+estimates+by+6.6%25.%0A%E2%80%A2+4%2C+Vertex+Pharmaceuticals+released+its+Q2+results%2C+and+its+shares+plummeted+20.6%25.%0A%E2%80%A2+Longer+term%2C+VRTX+has+plun%E2%80%A6%0Ahttps%3A%2F%2Ffinance.yahoo.com%2Fm%2F59379879-7a6a-342d-9125-5ff3f88c0168%2Fis-vertex-pharmaceuticals.html" target="_blank" rel="noopener">Share on X</a>
      </div>
      <div class="footer">© 2025 · Built from digest_5bullets.md</div>
    </div>
  </div>
</body>
</html>
